Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

BACKGROUND: Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement in progression-free survival with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlumberger, M, Elisei, R, Müller, S, Schöffski, P, Brose, M, Shah, M, Licitra, L, Krajewska, J, Kreissl, M C, Niederle, B, Cohen, E E W, Wirth, L, Ali, H, Clary, D O, Yaron, Y, Mangeshkar, M, Ball, D, Nelkin, B, Sherman, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834040/
https://www.ncbi.nlm.nih.gov/pubmed/29045520
http://dx.doi.org/10.1093/annonc/mdx479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834040/
https://www.ncbi.nlm.nih.gov/pubmed/29045520
http://dx.doi.org/10.1093/annonc/mdx479

Ejemplares similares